MedPath

Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study

Completed
Conditions
Fibromuscular Dysplasia
Renal Artery Stenosis
Registration Number
NCT02528149
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Fibromuscular dysplasia (FMD) is localized structural defects in the arterial wall, whose innate or acquired character is still unknown. This segmental non atheromatous injury, leads to stenosis of the arteries of small and medium caliber. Renal arteries are the most commonly affected with 60-75% of total fibrodysplasia. Three histological subtypes have been described: intimal, medial and peri-medial. They are not mutually exclusive and can be observed in the same patient.

This is a rare blood disease, occurring in children and young adults. In this young population with long life expectancy, these aneurysmal lesion are associated with 10% risk of rupture. To date, no data have shown in the literature that FMD is link to genetic causes, or if there is specific histopathologic lesions for non-atherosclerotic renal artery aneurysms.

To answer these questions, Cardiovascular Surgery Unit of the University Hospital of Saint-Etienne, French national reference center for renal artery surgery, in association with the Reference Center for Rare Vascular Disease in Paris, designed the first study for pathological and genetic characteristics of dysplastic renal artery aneurysms in young patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria
  • Patients with one or more Renal artery aneurysm (RAA), not eligible for endovascular treatment, have been operated at the Hospital of Saint-Etienne, with tissue (adjacent part and aneurysm) cryopreserved in liquid nitrogen in renal lab and then sent in genetic lab in Georges Pompidou European Hospital (EHGP ).
  • Patient (or parent/person having parental authority) Affiliate or entitled to a social security scheme.
  • Signature of patient consent (or parents or holder of parental authority)
Exclusion Criteria
  • Patient not included in the tissue collection in Georges Pompidou European Hospital (EHGP ).
  • Patient refusing to participate in the study and / or genetic analysis or, for juvenile patients, parents or holder of parental authority refusing the minor patient to be involved in the study and / or genetic analysis.
  • Patient with FMD whose samples in the tissue collection did not concern aneurysm.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
anatomopathological characteristics of renal aneurysmsday 1

Anatomopathological criteria is a composite outcome : Presence of a media thickness, the media disappearance zones, loss of smooth muscle cells (SMC) in the media with replacement by fibrosis, disorganization of SMC, aneurysms, dissections, discontinuity of the internal elastic lamina, and intimal thickening due to myointimal hyperplasia, abnormalities of proteins of the extracellular matrix.

Secondary Outcome Measures
NameTimeMethod
genetic markers in blood samplesday 1

identify specific genetic markers (mutation, variant) to characterize genes involved in fibromuscular dysplasia

genetic markers in aneurysm tissueday 1

identify specific genetic markers (mutation, variant) to characterize genes involved in fibromuscular dysplasia

Trial Locations

Locations (17)

CH Henri Mondor

🇫🇷

Aurillac, France

CH Louis Pasteur

🇫🇷

Bagnols sur Cèze, France

CHU Saint-Jacques

🇫🇷

Besançon, France

Groupe Hospitalier Pellegrin

🇫🇷

Bordeaux, France

Clinique Saint-Germain

🇫🇷

Brive-La-Gaillarde, France

Centre Hospitalier A. Gayraud

🇫🇷

Carcassonne, France

CH W. Morey

🇫🇷

Chalon sur Saone, France

Hôpital Gabriel Montpied

🇫🇷

Clermont-Ferrand, France

CH Emile Roux

🇫🇷

Le Puy en Velay, France

Hôpital Jeanne de Flandre

🇫🇷

Lille, France

Scroll for more (7 remaining)
CH Henri Mondor
🇫🇷Aurillac, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.